Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

被引：3
|
作者：
Ailawadhi, Sikander [1 ]
Stiff, Patrick J. [2 ]
Ibrahim, Emad [3 ]
Vallurupalli, Anusha [4 ]
Cull, Elizabeth H. [5 ]
Green, Damian J. [6 ]
Oliver, Kate [7 ]
Longcor, Jarrod [8 ]
机构：
[1] Mayo Clin, Div Hematol Oncol, Dept Med, Jacksonville, FL 32224 USA
[2] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA
[3] Redlands Community Hosp, Redlands, CA USA
[4] Univ Kansas, Canc Ctr, Westwood, KS USA
[5] Prisma Hlth, Canc Inst, Greenville, SC USA
[6] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[7] Cellectar Biosci, Madison, WI USA
[8] Cellectar Biosci, Florham Pk, NJ USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131014
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
144
引用
收藏
页数：3
相关论文
共 50 条
  • [1] CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Longcor, Jarrod
    Ailawadhi, Sikander
    Oliver, Kate
    Callander, Natalie
    Stiff, Patrick
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E356 - E357
  • [2] Relationship of Carfilzomib Dosing and Duration of Therapy (DOT) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Harvey, R. Donald
    Chen, Yaozhu J.
    Lethen, Jan
    Mahue, Maya
    [J]. BLOOD, 2015, 126 (23)
  • [3] Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Anum, Babar
    Hina, Zubair
    Mainoma, Bano
    Sana, Rafique
    Arzu, Shahid
    Maham, Babar
    Waleed, Madeeha S.
    Arslan, Inayat
    Danish, Safi
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S29 - S29
  • [4] Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Maharaj, Michele
    Oliver, Katherine
    Callander, Natalie Scott
    [J]. BLOOD, 2016, 128 (22)
  • [5] Therapy of relapsed and/or refractory multiple myeloma (RRMM)
    Engelhardt, M.
    Waesch, R.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 14 - 14
  • [6] CLR 131 IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC MALIGNANCIES
    Otto, Mario
    Desantes, Kenneth
    Puccetti, Diane
    Cho, Steve
    Hall, Lance
    Oliver, Kate
    Longcor, Jarrod
    [J]. PEDIATRIC BLOOD & CANCER, 2020, 67 : S115 - S115
  • [7] Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma
    Longcor, Jarrod
    Oliver, Kate
    [J]. BLOOD, 2019, 134
  • [8] CLR 131 IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC MALIGNANCIES
    Puccetti, Diane
    Otto, Mario
    Morgenstern, Daniel
    DeSantes, Kenneth
    Cho, Steven
    Hall, Lance
    Oliver, Kate
    Longcor, Jarrod
    [J]. NEURO-ONCOLOGY, 2020, 22 : 305 - 305
  • [9] Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Abadier, Michael
    Estevam, Jose
    Berg, Deborah
    Fedyk, Eric Robert
    [J]. BLOOD, 2020, 136
  • [10] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    [J]. HAEMATOLOGICA, 2020, 105 : 13 - 14
12345